Biovica: Committed to developing and commercializing novel blood-based biomarker assays.
Biovica is a Swedish biotech company founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.
Clinical validation: The DiviTum® TKa test was selected for support and funding by the European Commission Horizon 2020 phase 2 program.
Improved care for cancer patients
To transform management of cancer care through innovative biomarker-based tests
We work as a team, supporting each other to create success.
We use technology to create innovative and sustainable solutions to fulfill our mission.
We act ethically and responsibly to build trust.
What oncologists say
Numbers of patients in studies